
ImmunityBio, Inc.: updates and filings
Price
$6.26
November 17, 2026Market cap $6.4B
What Ploutos Investor adds for ImmunityBio
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Nov 9, 2026Regulation FD disclosureForm8-K
- Oct 14, 2026Regulation FD disclosureForm8-K
- Aug 6, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Results of operationsForm8-K
- Jul 30, 2026Regulation FD disclosureForm8-K
- Jun 10, 2026Shareholder voteForm8-K
- May 18, 2026Material agreement entered, Regulation FD disclosureForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 9, 2026Results of operationsForm8-K
- Apr 6, 2026Regulation FD disclosureForm8-K
- Mar 31, 2026Material agreement entered, new material financial obligation, Regulation FD disclosure, other material eventsForm8-K
- Feb 25, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 23, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 23, 2026Results of operationsForm8-K
- Feb 18, 2026Other material eventsForm8-K
- Jan 26, 2026Material agreement enteredForm8-K
- Jan 15, 2026Results of operationsForm8-K
- Jan 14, 2026Other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Nov 9, 2026 | 8-K | Regulation FD disclosure | Document |
| Oct 14, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 6, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations | Document |
| Jul 30, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 10, 2026 | 8-K | Shareholder vote | Document |
| May 18, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 9, 2026 | 8-K | Results of operations | Document |
| Apr 6, 2026 | 8-K | Regulation FD disclosure | Document |
| Mar 31, 2026 | 8-K | Material agreement entered, new material financial obligation, Regulation FD disclosure, other material events | Document |
| Feb 25, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 23, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 23, 2026 | 8-K | Results of operations | Document |
| Feb 18, 2026 | 8-K | Other material events | Document |
| Jan 26, 2026 | 8-K | Material agreement entered | Document |
| Jan 15, 2026 | 8-K | Results of operations | Document |
| Jan 14, 2026 | 8-K | Other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 29, 2005.
The full analysis
What do ImmunityBio's filings show?
The filings are where every one of ImmunityBio's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.